Vericel Corporation 2021 Form 10-K Summary
Business context and reporting period
Vericel is a commercial-stage biopharmaceutical company focused on autologous cell therapies for sports medicine and severe burn care. It markets FDA-approved MACI for knee cartilage repair and Epicel for extensive burns in the United States, and holds North American rights to pre-commercial NexoBrid for burn debridement. The filing covers the fiscal year ended December 31, 2021, filed February 24, 2022.
Financial performance and liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Total revenue | $156.2 million | $124.2 million | 25.8% increase |
| Gross profit | $106.0 million | $84.2 million | 25.9% increase |
| Gross margin | 67.9% | 67.8% | Broadly stable |
| Operating income (loss) | $(7.9) million | $2.4 million | Declined $10.2 million |
| Operating margin | (5.0)% | 1.9% | Lower |
| Net income (loss) | $(7.5) million | $2.9 million | Turned to loss |
| Net margin | (4.8)% | 2.3% | Lower |
| Operating cash flow | $29.0 million | $17.6 million | 65.3% increase |
- MACI revenue was $111.6 million, up 18.1%; Epicel revenue was $41.5 million, up 50.8%; and NexoBrid revenue was $3.1 million versus $2.2 million in 2020.
- Research and development expense increased 25.1% to $16.3 million. Selling, general and administrative expense increased 41.8% to $97.6 million, driven principally by higher stock-based compensation, headcount, marketing, and patient reimbursement support.
- Non-cash stock-based compensation increased to $34.3 million from $13.8 million, materially affecting reported operating results.
- Cash, cash equivalents and restricted cash totaled $68.5 million at year-end. Short- and long-term investments totaled $60.8 million, resulting in approximately $129.3 million of cash, cash equivalents and investments.
- Accounts receivable were $37.4 million and inventory was $13.4 million. The MACI allowance for uncollectible consideration was $7.0 million.
- The company reported no traditional borrowings or funded debt. Lease liabilities totaled approximately $50.2 million on a present-value basis, with total remaining lease payments of $66.5 million.
- Capital expenditures were $7.9 million, primarily for manufacturing upgrades. Financing cash flow of $9.2 million primarily reflected stock-option exercises and employee stock purchases.
- Accumulated deficit was $383.3 million. Management stated that existing cash, cash equivalents and investments were expected to support current operations for at least 12 months after issuance of the financial statements.
Material changes versus the prior comparable period
- Revenue growth reflected increased MACI and Epicel volumes and additional NexoBrid deliveries to BARDA for emergency preparedness.
- Despite higher revenue and stable gross margin, the company moved from a $2.4 million operating profit and $2.9 million net profit in 2020 to operating and net losses in 2021. The principal pressure was substantially higher selling, general and administrative expense, including $16.5 million of incremental stock-based compensation.
- Operating cash flow improved to $29.0 million, aided by non-cash stock compensation, lease amortization and depreciation, partially offset by increased accounts receivable and inventory.
- MACI procedures slowed during the third and fourth quarters as Delta and Omicron disruptions affected elective surgeries, hospital staffing, physician availability and patient treatment decisions. Epicel was less affected because it is primarily used in emergency burn care.
- On June 29, 2021, the FDA issued a complete response letter for the NexoBrid BLA. The filing identifies unresolved chemistry, manufacturing and controls matters, required manufacturing-site inspections in Israel and Taiwan, questions related to GCP inspection observations, and a requested safety update.
- On January 28, 2022, Vericel entered into a lease for approximately 126,000 square feet of future manufacturing, laboratory and office space in Burlington, Massachusetts. The lease includes an estimated tenant-improvement allowance of approximately $25.1 million and required a $6.0 million cash-collateralized letter of credit.
- Vericel established a $200 million at-the-market equity program in August 2021, but had sold no shares under the program through year-end.
Guidance, outlook, commentary and risks
The filing does not provide formal 2022 revenue, earnings or margin guidance. Management’s stated strategy is to expand MACI adoption, increase Epicel utilization, pursue potential NexoBrid commercialization, and ultimately generate operating income by growing commercial revenue faster than commercial expenses.
- COVID-19 remains a key uncertainty, particularly for elective MACI procedures, hospital staffing, transportation and supply availability. The company cannot reliably estimate the pandemic’s future effect on utilization or revenue.
- NexoBrid remains unapproved in the United States. Timing and ultimate approval depend on MediWound’s response to the FDA, additional CMC information, facility inspections, GCP matters and safety data. BARDA funding and procurement commitments may also be terminated or reduced.
- U.S. commercial manufacturing for MACI and Epicel depends on a single Cambridge, Massachusetts facility. The company also relies on single- or limited-source suppliers, including Matricel for the MACI collagen membrane.
- MACI revenue is exposed to payer reimbursement, contractual allowance estimates and collection risk. A 50-basis-point change in the estimated uncollectible percentage would have changed 2021 revenue by approximately $0.3 million.
- Revenue and cash flow are subject to substantial quarterly variability. Historically, MACI volumes have been concentrated in the fourth quarter, while Epicel revenue is inherently unpredictable because severe burns are infrequent and sporadic.
- Long-term risks include continued operating losses, the need for additional capital, reimbursement pressure, regulatory compliance, product liability, cybersecurity, competition, intellectual-property limitations and the ability to scale manufacturing.
- The company had no material legal proceedings reported and stated that its disclosure controls and internal control over financial reporting were effective as of December 31, 2021. PwC issued unqualified audit opinions.
Important facts for investors to verify
- Confirm the durability of MACI and Epicel volume growth and whether elective-surgery disruptions continue to affect 2022 results.
- Track NexoBrid’s BLA resubmission, FDA facility inspections, CMC remediation and the potential timing of U.S. approval.
- Assess whether selling, general and administrative spending and stock-based compensation moderate sufficiently to support a return to operating profitability.
- Monitor cash burn, operating cash flow, capital expenditures, the Burlington facility lease and any future use of the $200 million ATM program.
- Review MACI payer collections, the $7.0 million contractual allowance and changes in reimbursement rates or coverage policies.
- Evaluate single-facility manufacturing capacity, supplier concentration and the company’s ability to scale production without margin deterioration.